OSI Oncology: Shifting the Paradigm

OSI’s Oncology research strategy is based on an expectation for the future of cancer therapy. Over the coming years, we predict a continued development of the use of oral targeted therapies both as single agents and in combination with other molecular targeted therapies. Oncology research at OSI couples the identification of pharmacodynamic, surrogate, and diagnostic markers to help in monitoring efficacy and selecting sensitive patients during development and commercialization.

Our research organization is focused on the discovery of novel small molecule compounds targeted against the underlying molecular mechanisms of the pathogenesis of cancer. Our strategy is to develop mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition (EMT) in the development of cancer.

Vision Statement: OSI’s Oncology research team strives to be a world leader in the development of Molecular Targeted Therapies for the treatment of cancer through exploiting the science underpinning the Epithelial Mesenchymal Transition.

Academic Researchers: For more information on OSI compounds for academic research, click here.